NASDAQ · KPTI
Healthcare · Biotechnology
$2.03
Down-$0.06 (-2.71%)
Updated Aug 13, 2026, 5:20 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
KPTI closed at $2.03 after 21 trading sessions, down 78.70% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $2.10 | $2.1491 | $2.00 | $2.03 | 1.84M |
| Aug 11, 2026 | $1.93 | $2.18 | $1.93 | $2.10 | 1.96M |
| Aug 10, 2026 | $2.14 | $2.1786 | $1.915 | $1.96 | 1.8M |
| Aug 7, 2026 | $1.96 | $2.12 | $1.91 | $2.12 | 1.79M |
| Aug 6, 2026 | $1.88 | $2.005 | $1.88 | $1.95 | 1.19M |
| Aug 5, 2026 | $1.94 | $2.055 | $1.88 | $1.91 | 2.38M |
| Aug 4, 2026 | $2.00 | $2.11 | $1.94 | $1.96 | 3.79M |
| Aug 3, 2026 | $1.94 | $2.05 | $1.80 | $1.97 | 4.51M |
| Jul 31, 2026 | $2.19 | $2.43 | $1.80 | $1.92 | 22.4M |
| Jul 30, 2026 | $6.98 | $7.09 | $6.555 | $7.01 | 4.54M |
| Jul 29, 2026 | $7.04 | $7.47 | $6.73 | $6.86 | 436.89K |
| Jul 28, 2026 | $7.10 | $7.14 | $6.75 | $7.09 | 531.29K |
| Jul 27, 2026 | $7.45 | $7.84 | $7.015 | $7.09 | 527.47K |
| Jul 24, 2026 | $7.15 | $7.605 | $6.992 | $7.41 | 900.25K |
| Jul 23, 2026 | $7.14 | $7.19 | $6.75 | $7.09 | 680.13K |
| Jul 22, 2026 | $7.92 | $8.02 | $7.05 | $7.18 | 713.64K |
| Jul 21, 2026 | $7.49 | $8.27 | $7.46 | $7.865 | 943.08K |
| Jul 20, 2026 | $9.40 | $9.45 | $6.485 | $7.47 | 2.33M |
| Jul 17, 2026 | $9.35 | $9.59 | $9.31 | $9.51 | 205.24K |
| Jul 16, 2026 | $9.55 | $9.84 | $9.36 | $9.38 | 236.38K |
| Jul 15, 2026 | $9.85 | $9.86 | $9.38 | $9.53 | 316.49K |
The latest Smart Investors Daily articles mentioning KPTI.
KPTI research
Company profile and research snapshot.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | Piper Sandler | Overweight | — |
| Jul 31, 2026 | HC Wainwright & Co. | Neutral | — |
| May 6, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | Piper Sandler | Overweight | — |
| Mar 30, 2026 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Jul 31, 2026
Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the price target from $16 to $7.
Benzinga · Jul 31, 2026
HC Wainwright & Co. analyst Robert Burns downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral and lowers the price target from $13 to $3.
SeekingAlpha · Jul 21, 2026
Karyopharm Therapeutics markets selinexor in multiple myeloma and is running trials in multiple myeloma. Read the outlook on KPTI stock here.
SeekingAlpha · Jun 18, 2026
Karyopharm (KPTI) gets a reiterated Sell as Xpovio stagnates, trials disappoint, and cash burn rises. Click here to read my most recent analysis of the stock.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KPTI.
